AI ASSISTANT
Ask DrugCentral
Explore drug information in your own words.
Type a question in the search bar above to get started. Each question is answered independently.
Try a sample question
Select a question to fill the search bar, then submit it or edit it first.
AI can make mistakes. Verify answers against the original sources before relying on them.
clindamycin palmitate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 679 | 36688-78-5 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BA (Bioavailability) | 87 % |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2A,ACVR2B,ACVRL1,AKT2,AKT3,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,GRK2,GSK3B,ITK,JAK2,JAK3,MAP2K6,MAP3K21,MAP3K7,MAPK10,MAPK7,MAPKAPK2,NTRK2,PDK1,PDK2,PDK4,PDPK1,PIK3CB,PIK3CG,PIM2,PRKDC,SIK2,STK33,SYK,TEK,TGFBR1,ZAP70 | 45 | |||
| kinase-selectivity-class | AXL,CDK4,EIF2AK3,GRK2,MAP2K6,TEK | 6 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 | |||
| pld-class | Phospholipidosis risk class (1 = positive, 0 = negative) | 1 | Moderate | 0.75 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| April 7, 1986 | FDA | PHARMACIA AND UPJOHN |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| MeSH PA | D000890 | Anti-Infective Agents |
| MeSH PA | D000900 | Anti-Bacterial Agents |
| MeSH PA | D004791 | Enzyme Inhibitors |
| MeSH PA | D011500 | Protein Synthesis Inhibitors |
| FDA CS | M0515779 | Lincosamides |
| FDA PE | N0000009982 | Decreased Sebaceous Gland Activity |
| FDA EPC | N0000175443 | Lincosamide Antibacterial |
| CHEBI has role | CHEBI:35703 | xenobiotic |
| CHEBI has role | CHEBI:78298 | environmental contaminant |
| FDA PE | N0000175731 | Neuromuscular Blockade |
Drug Use | Suggest Off label Use Form| |View source of the data|
None
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 12.02 | acidic |
| pKa2 | 13.71 | acidic |
| pKa3 | 7.52 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
None
External reference:
| ID | Source |
|---|---|
| D01990 | KEGG_DRUG |
| 25507-04-4 | SECONDARY_CAS_RN |
| 21235 | RXNORM |
| C0055880 | UMLSCUI |
| CLY | PDB_CHEM_ID |
| CHEMBL1201289 | ChEMBL_ID |
| CHEMBL1200632 | ChEMBL_ID |
| C000489 | MESH_SUPPLEMENTAL_RECORD_UI |
| C501Z28AFG | UNII |
| 16052039 | PUBCHEM_CID |
| 174519 | MMSL |
| 4466 | MMSL |
| 4468 | MMSL |
| d00043 | MMSL |
| 002794 | NDDF |
| 002797 | NDDF |
| 007738 | NDDF |
| 372786004 | SNOMEDCT_US |
| 47663000 | SNOMEDCT_US |
| 58883005 | SNOMEDCT_US |
| C0008947 | UMLSCUI |
| CHEBI:135866 | CHEBI |
| DB01190 | DRUGBANK_ID |
| 446598 | PUBCHEM_CID |
| 2550 | INN_ID |
| 4018083 | VANDF |
| 4019683 | VANDF |
| D002981 | MESH_DESCRIPTOR_UI |
| CHEBI:3745 | CHEBI |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Cleocin Pediatric | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0009-0760 | GRANULE, FOR SOLUTION | 75 mg | ORAL | ANDA | 25 sections |
| Cleocin Pediatric | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0009-0760 | GRANULE, FOR SOLUTION | 75 mg | ORAL | ANDA | 25 sections |
| Clindamycin Palmitate Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10135-569 | SOLUTION | 75 mg | ORAL | ANDA | 25 sections |
| Clindamycin Palmitate Hydrochloride (Pediatric) | Human Prescription Drug Label | 1 | 16714-483 | SOLUTION | 75 mg | ORAL | ANDA | 24 sections |
| clindamycin palmitate hydrochloride | Human Prescription Drug Label | 1 | 23155-603 | GRANULE, FOR SOLUTION | 75 mg | ORAL | ANDA | 14 sections |
| Clindamycin Palmitate Hydrochloride(Pediatric) | HUMAN PRESCRIPTION DRUG LABEL | 1 | 53746-468 | POWDER, FOR SOLUTION | 75 mg | ORAL | ANDA | 13 sections |
| Cleocin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54868-5833 | GRANULE, FOR SOLUTION | 75 mg | ORAL | ANDA | 26 sections |
| Clindamycin Palmitate Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 62135-926 | GRANULE, FOR SOLUTION | 75 mg | ORAL | ANDA | 14 sections |
| CLINDAMYCIN PALMITATE HYDROCHLORIDE(Pediatric) | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63629-2391 | GRANULE, FOR SOLUTION | 75 mg | ORAL | ANDA | 22 sections |
| CLINDAMYCIN PALMITATE HYDROCHLORIDE(Pediatric) | Human Prescription Drug Label | 1 | 64980-511 | GRANULE, FOR SOLUTION | 75 mg | ORAL | ANDA | 22 sections |
| Clindamycin Palmitate Hydrochloride(Pediatric) | HUMAN PRESCRIPTION DRUG LABEL | 1 | 65162-468 | POWDER, FOR SOLUTION | 75 mg | ORAL | ANDA | 13 sections |
| Clindamycin Palmitate Hydrochloride (Pediatric) | Human Prescription Drug Label | 1 | 65862-596 | SOLUTION | 75 mg | ORAL | ANDA | 23 sections |
| CLINDAMYCIN PALMITATE HYDROCHLORIDE(Pediatric) | HUMAN PRESCRIPTION DRUG LABEL | 1 | 72162-1809 | GRANULE, FOR SOLUTION | 75 mg | ORAL | ANDA | 22 sections |